Figure 2: Mechanism of action of Brentuximab Vedotin. Brentuximab vedotin is internalized into CD30 positive cell through clathrin-mediated endocytosis. The vesicle containing the antibody-drug conjugate fuses with the lysosome. Cathepsin in the lysosome cleaves the valine-citrulline dipeptide linker and releases MMAE (monomethyl auristatin E) into the cell thus inhibiting microtubule polymerization. The MMAE diffuses out of the cell due to inherent membrane permeability and acts on the CD30 negative bystander cells.